This is even more true for people with type 2 diabetes, since sodium−glucose cotransporter 2 (SGLT2) inhibitors provide both glucose lowering and cardiovascular protection, showing promising effects on cardiovascular outcomes [15, 16]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.